Dueñas-Gutiérrez, C.; Buzón, L.; Pedrero-Tomé, R.; Iribarren, J.A.; De los Santos, I.; De la Fuente, S.; Pousada, G.; Moran, M.A.; Moreno, E.; Ferreira, E.;
et al. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV. Viruses 2023, 15, 936.
https://doi.org/10.3390/v15040936
AMA Style
Dueñas-Gutiérrez C, Buzón L, Pedrero-Tomé R, Iribarren JA, De los Santos I, De la Fuente S, Pousada G, Moran MA, Moreno E, Ferreira E,
et al. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV. Viruses. 2023; 15(4):936.
https://doi.org/10.3390/v15040936
Chicago/Turabian Style
Dueñas-Gutiérrez, Carlos, Luis Buzón, Roberto Pedrero-Tomé, José A. Iribarren, Ignacio De los Santos, Sara De la Fuente, Guillermo Pousada, Miguel Angel Moran, Estela Moreno, Eva Ferreira,
and et al. 2023. "Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV" Viruses 15, no. 4: 936.
https://doi.org/10.3390/v15040936
APA Style
Dueñas-Gutiérrez, C., Buzón, L., Pedrero-Tomé, R., Iribarren, J. A., De los Santos, I., De la Fuente, S., Pousada, G., Moran, M. A., Moreno, E., Ferreira, E., Gómez, J., & Troya, J.
(2023). Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV. Viruses, 15(4), 936.
https://doi.org/10.3390/v15040936
